Another phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DNL747, another RIPK1 inhibitor, in 16 AD patients is ongoing in the US and the Netherlands (NCT03757325, https://clinicaltrials.gov, accessed on 1 January 2021). This evidence concerns the gene RIPK1 and Alzheimer disease.